Heart Disease Clinical Trials in New York

Showing 161-180 of 585 trials

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

NCT04766892

This is a Phase 2a proof-of-concept study to assess safety, tolerability, and preliminary efficacy of mavacamten treatment on biomarker levels in participants with heart failure with preserved ejection fraction (HFpEF) and elevation of NT-proBNP with or without elevation of cTnT. Data from this study will inform future study designs of mavacamten in patients with HFpEF.

Heart Failure With Preserved Ejection Fraction

Bristol-Myers Squibb30 participantsStarted Mar 2021

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +18 more locations

COMPLETEDPhase 3< 1 mile

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634

The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days post-decompensation.

Heart Failure With Preserved Ejection Fraction (HFpEF)

Novartis Pharmaceuticals467 participantsStarted Jun 2019

Irvine, California, United States • Long Beach, California, United States • Los Angeles, California, United States +94 more locations

A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Disease Trials in Other Cities

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

FUnctional diagnoSIs of corONary Stenosis (FUSION)

Early Feasibility Evaluation of the AccuCinch® Ventricular Restoration System in Patients With Heart Failure and Reduced Ejection Fraction

The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Benefits of Microcor in Ambulatory Decompensated Heart Failure

Heart Failure Optimization Study

Benefits of µCor in Ambulatory Decompensated Heart Failure

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

Cardiovascular Risk Screening and Risk Reduction in Women Vets

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Acorai Machine Learning Generalization (MLG) Study

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Effect of Fetal Aortic Valvuloplasty on Outcomes

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function

Other Conditions in New York